Download PDF
Journal of Pediatric Epilepsy 2016; 05(04): 159-167
DOI: 10.1055/s-0036-1584915
Review Article
Georg Thieme Verlag KG Stuttgart · New York

The History of Development of Pharmacologic and NonPharmacologic Treatment of Pediatric Epilepsy

Mitra Habibi
1   Department of Pharmacy Practice, University of Illinois, Chicago, Illinois, United States
,
Saba Ahmad
2   Department of Pediatrics, University of Illinois, Chicago, Illinois, United States
,
Claudine Sinsioco
2   Department of Pediatrics, University of Illinois, Chicago, Illinois, United States
› Author Affiliations
Further Information

Publication History

14 December 2015

15 January 2016

Publication Date:
29 June 2016 (online)

    Permissions and Reprints

Abstract

Epilepsy is a common childhood neurological disorder in the United States. Current strategies for treatment of epilepsy in this population include trials with different antiepileptic drugs, vagal nerve stimulator, and ketogenic diet. Development of both pharmacologic and nonpharmacologic treatments in children should take into account their specific pharmacokinetic requirements as well as other ethical and practical challenges that exist for this population. As a result, in many instances detailed information on historical developments of these treatments in children is incomplete or lacking.

Keywords

children - epilepsy - antiepileptic drugs - historical development
 

  • References

  • 1 Russ SA, Larson K, Halfon N. A national profile of childhood epilepsy and seizure disorder. Pediatrics 2012; 129 (2) 256-264
    CrossrefPubMedGoogle Scholar
  • 2 Epilepsy Fast Facts. Centers for Disease Control and Prevention website. http://www.cdc.gov/epilepsy/basics/fast-facts.htm . Accessed April 29, 2015
    PubMed
  • 3 Chiron C, Kassai B, Dulac O, Pons G, Nabbout R. A revisited strategy for antiepileptic drug development in children: designing an initial exploratory step. CNS Drugs 2013; 27 (3) 185-195
    CrossrefPubMedGoogle Scholar
  • 4 Hauser WA. The prevalence and incidence of convulsive disorders in children. Epilepsia 1994; 35 (Suppl. 02) S1-S6
    PubMedGoogle Scholar
  • 5 Chiron C, Dulac O, Pons G. Antiepileptic drug development in children: considerations for a revisited strategy. Drugs 2008; 68 (1) 17-25
    CrossrefPubMedGoogle Scholar
  • 6 Katz R. FDA update. Epilepsy Res 2006; 68 (1) 85-94
    CrossrefPubMedGoogle Scholar
  • 7 Scott DF. The History of Epileptic Therapy: An Account of How Medication Was Discovered. Carnforth, Lancs, UK: Parthenon Publication Group; 1993
    Google Scholar
  • 8 Garofalo E. Clinical development of antiepileptic drugs for children. Neurotherapeutics 2007; 4 (1) 70-74
    CrossrefPubMedGoogle Scholar
  • 9 Pellock JM, Carman WJ, Thyagarajan V, Daniels T, Morris DL, D'Cruz O. Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. Neurology 2012; 79 (14) 1482-1489
    CrossrefPubMedGoogle Scholar
  • 10 López-Muñoz F, Ucha-Udabe R, Alamo C. The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat 2005; 1 (4) 329-343
    PubMedGoogle Scholar
  • 11 Yasiry Z, Shorvon SD. How phenobarbital revolutionized epilepsy therapy: the story of phenobarbital therapy in epilepsy in the last 100 years. Epilepsia 2012; 53 (Suppl. 08) 26-39
    PubMedGoogle Scholar
  • 12 Friedlander WJ. Putnam, Merritt, and the discovery of Dilantin. Epilepsia 1986; 27 (Suppl. 03) S1-S20
    PubMedGoogle Scholar
  • 13 Bialer M. How did phenobarbital's chemical structure affect the development of subsequent antiepileptic drugs (AEDs)?. Epilepsia 2012; 53 (Suppl. 08) 3-11
    PubMedGoogle Scholar
  • 14 Slaughter LA, Patel AD, Slaughter JL. Pharmacological treatment of neonatal seizures: a systematic review. J Child Neurol 2013; 28 (3) 351-364
    CrossrefPubMedGoogle Scholar
  • 15 Kimball OP. The treatment of epilepsy with sodium diphenyl hydantoinate. JAMA 1939; 112: 1244-1245
    CrossrefPubMedGoogle Scholar
  • 16 Browne TR, Dreifuss FE, Dyken PR , et al. Ethosuximide in the treatment of absence (peptit mal) seizures. Neurology 1975; 25 (6) 515-524
    CrossrefPubMedGoogle Scholar
  • 17 Santavuori P. Absence seizures: valproate or ethosuximide?. Acta Neurol Scand Suppl 1983; 97: 41-48
    PubMedGoogle Scholar
  • 18 Sato S, White BG, Penry JK, Dreifuss FE, Sackellares JC, Kupferberg HJ. Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982; 32 (2) 157-163
    CrossrefPubMedGoogle Scholar
  • 19 Capovilla G, Beccaria F, Veggiotti P, Rubboli G, Meletti S, Tassinari CA. Ethosuximide is effective in the treatment of epileptic negative myoclonus in childhood partial epilepsy. J Child Neurol 1999; 14 (6) 395-400
    CrossrefPubMedGoogle Scholar
  • 20 Motika P, Smith MC. Carbamazepine. In: Panayiotopoulos CP, eds. The Atlas of Epilepsies. New York: Springer; 2010: 1713-1718
    CrossrefGoogle Scholar
  • 21 Jongmans JW. Report on the anti-epileptic action of Tegretol. Epilepsia 1964; 5: 74-82
    CrossrefPubMedGoogle Scholar
  • 22 Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959-2009. Epilepsia 2009; 50 (Suppl. 03) 93-130
    CrossrefPubMedGoogle Scholar
  • 23 de Silva M, MacArdle B, McGowan M , et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347 (9003) 709-713
    CrossrefPubMedGoogle Scholar
  • 24 Loscher W. The discovery of valproate. In: Loscher W, ed. Valproate. Basal: Birkhauser; 1999: 1-3
    CrossrefGoogle Scholar
  • 25 Peterson GM, Naunton M. Valproate: a simple chemical with so much to offer. J Clin Pharm Ther 2005; 30 (5) 417-421
    CrossrefPubMedGoogle Scholar
  • 26 Simon D, Penry JK. Sodium di-N-propylacetate (DPA) in the treatment of epilepsy. A review. Epilepsia 1975; 16 (4) 549-573
    CrossrefPubMedGoogle Scholar
  • 27 Marson AG, Al-Kharusi AM, Alwaidh M , et al; SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369 (9566) 1016-1026
    CrossrefPubMedGoogle Scholar
  • 28 Shields WD, Pellock JM. Vigabatrin 35 years later-from mechanism of action to benefit-risk considerations. Acta Neurol Scand 2011; 124: S1-S4
    PubMedGoogle Scholar
  • 29 Tolman JA, Faulkner MA. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. Expert Opin Pharmacother 2009; 10 (18) 3077-3089
    CrossrefPubMedGoogle Scholar
  • 30 Sabril (vigabatrin) [package insert], Deerfield, IL: Lundbeck; 2013
  • 31 Weisler RH, Calabrese JR, Bowden CL, Ascher JA, DeVeaugh-Geiss J, Evoniuk G. Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence. J Affect Disord 2008; 108 (1–2) 1-9
    CrossrefPubMedGoogle Scholar
  • 32 Besag FM, Dulac O, Alving J, Mullens EL. Long-term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy. Seizure 1997; 6 (1) 51-56
    CrossrefPubMedGoogle Scholar
  • 33 Eriksson AS, Nergårdh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998; 39 (5) 495-501
    CrossrefPubMedGoogle Scholar
  • 34 Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P ; Lamictal Lennox-Gastaut Study Group. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1997; 337 (25) 1807-1812
    CrossrefPubMedGoogle Scholar
  • 35 Duchowny M, Pellock JM, Graf WD , et al; Lamictal Pediatric Partial Seizure Study Group. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology 1999; 53 (8) 1724-1731
    CrossrefPubMedGoogle Scholar
  • 36 Pellock JM, Faught E, Leppik IE, Shinnar S, Zupanc ML. Felbamate: consensus of current clinical experience. Epilepsy Res 2006; 71 (2–3) 89-101
    CrossrefPubMedGoogle Scholar
  • 37 Carmant L, Holmes GL, Sawyer S, Rifai N, Anderson J, Mikati MA. Efficacy of felbamate in therapy for partial epilepsy in children. J Pediatr 1994; 125 (3) 481-486
    CrossrefPubMedGoogle Scholar
  • 38 The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328 (1) 29-33
    CrossrefPubMedGoogle Scholar
  • 39 French J, Smith M, Faught E, Brown L. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 1999; 52 (8) 1540-1545
    CrossrefPubMedGoogle Scholar
  • 40 Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm 2003; 9 (6) 559-568
    PubMedGoogle Scholar
  • 41 Maryanoff BE. Sugar sulfamates for seizure control: discovery and development of topiramate, a structurally unique antiepileptic drug. Curr Top Med Chem 2009; 9 (11) 1049-1062
    CrossrefPubMedGoogle Scholar
  • 42 Rosenfeld WE, Doose DR, Walker SA, Baldassarre JS, Reife RA. A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol 1999; 20 (5) 339-344
    CrossrefPubMedGoogle Scholar
  • 43 Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G ; Topiramate YP Study Group. A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999; 52 (7) 1338-1344
    CrossrefPubMedGoogle Scholar
  • 44 Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G ; Topiramate YL Study Group. A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999; 52 (9) 1882-1887
    CrossrefPubMedGoogle Scholar
  • 45 Albsoul-Younes AM, Salem HA, Ajlouni SF, Al-Safi SA. Topiramate slow dose titration: improved efficacy and tolerability. Pediatr Neurol 2004; 31 (5) 349-352
    CrossrefPubMedGoogle Scholar
  • 46 Guerrini R, Carpay J, Groselj J , et al; TOP-INT-51 Investigators' Group. Topiramate monotherapy as broad-spectrum antiepileptic drug in a naturalistic clinical setting. Seizure 2005; 14 (6) 371-380
    CrossrefPubMedGoogle Scholar
  • 47 Trileptal. (oxcarbazepine) [package insert]. East Hanover, NJ: Novartis; 2014
    Google Scholar
  • 48 Beydoun A, Sachdeo RC, Rosenfeld WE , et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 2000; 54 (12) 2245-2251
    CrossrefPubMedGoogle Scholar
  • 49 Glauser TA, Nigro M, Sachdeo R , et al; The Oxcarbazepine Pediatric Study Group. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 2000; 54 (12) 2237-2244
    CrossrefPubMedGoogle Scholar
  • 50 Guerreiro MM, Vigonius U, Pohlmann H , et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27 (3) 205-213
    CrossrefPubMedGoogle Scholar
  • 51 Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia 2001; 42 (Suppl. 04) 13-18
    CrossrefPubMedGoogle Scholar
  • 52 Glauser TA, Gauer LJ, Chen L ; LEV N159 Study Group. Multicenter, double-blind, placebo-controlled trial of adjunctive levetiracetam (keppra) therapy (up to 60mg/kg/day) in pediatric patients with refractory partial epilepsy. Epilepsia 2004; 45 (Suppl. 07) 186-186
    PubMedGoogle Scholar
  • 53 Glauser TA, Pellock JM, Bebin EM , et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 2002; 43 (5) 518-524
    CrossrefPubMedGoogle Scholar
  • 54 Grosso S, Franzoni E, Coppola G , et al. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy. Seizure 2005; 14 (4) 248-253
    CrossrefPubMedGoogle Scholar
  • 55 Glauser TA, Ayala R, Elterman RD , et al; N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006; 66 (11) 1654-1660
    CrossrefPubMedGoogle Scholar
  • 56 Keppra (levetiracetam) [package insert]. Smyrna, GA: UCB; 2014
    Google Scholar
  • 57 Shah J, Shellenberger K, Canafax DM. Zonisamide. In: Levy RH, Mattson R, Meldrum BS, Perucca E, eds. Antiepileptic Drugs. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002: 873
    Google Scholar
  • 58 Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neurol 2002; 17 (2) 87-96
    CrossrefPubMedGoogle Scholar
  • 59 Zonegran (zonisamide) [package insert]. Teaneck, NJ: Eisai Inc; 2006
    Google Scholar
  • 60 Hsieh DT, Thiele EA. Efficacy and safety of rufinamide in pediatric epilepsy. Ther Adv Neurol Disord 2013; 6 (3) 189-198
    CrossrefPubMedGoogle Scholar
  • 61 Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008; 70 (21) 1950-1958
    CrossrefPubMedGoogle Scholar
  • 62 Sankar R. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs 2012; 26 (3) 229-244
    CrossrefPubMedGoogle Scholar
  • 63 Jensen HS, Nichol K, Lee D, Ebert B. Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for a₂- versus a₁-GABA(A)-receptor complexes. PLoS ONE 2014; 9 (2) e88456 DOI: 10.1371/journal.pone.0088456.
    CrossrefPubMedGoogle Scholar
  • 64 Giarratano M, Standley K, Benbadis SR. Clobazam for treatment of epilepsy. Expert Opin Pharmacother 2012; 13 (2) 227-233
    CrossrefPubMedGoogle Scholar
  • 65 Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can J Neurol Sci 1990; 17 (3) 317-319
    CrossrefPubMedGoogle Scholar
  • 66 Kalra V, Seth R, Mishra D, Saha NC. Clobazam in refractory childhood epilepsy. Indian J Pediatr 2010; 77 (3) 263-266
    CrossrefPubMedGoogle Scholar
  • 67 Conry JA, Ng YT, Paolicchi JM , et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009; 50 (5) 1158-1166
    CrossrefPubMedGoogle Scholar
  • 68 Conry JA, Ng YT, Kernitsky L , et al; OV-1004 Study Investigators. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia 2014; 55 (4) 558-567
    CrossrefPubMedGoogle Scholar
  • 69 Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA ; OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011; 77 (15) 1473-1481
    CrossrefPubMedGoogle Scholar
  • 70 Cramer JA, Sapin C, François C. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Acta Neurol Scand 2013; 128 (2) 91-99
    CrossrefPubMedGoogle Scholar
  • 71 Hanada T. The discovery and development of perampanel for the treatment of epilepsy. Expert Opin Drug Discov 2014; 9 (4) 449-458
    CrossrefPubMedGoogle Scholar
  • 72 Kerling F, Kasper BS. Efficacy of perampanel: a review of clinical trial data. Acta Neurol Scand Suppl 2013; 127 (197) 25-29
    CrossrefPubMedGoogle Scholar
  • 73 Temkin O. The Falling Sickness, 3rd ed. Baltimore, MD: Johns Hopkins University Press; 1994: 66-67
    Google Scholar
  • 74 Hippocrates, Galen. Hippocrates, The Writings of Hippocrates and Galen. . Coxe JR, trans. Philadelphia: Lindsay and Blakiston;1846. Available at http://oll.libertyfund.org/titles/1988#HippocratesGalen_0881_1721
    PubMedGoogle Scholar
  • 75 Galen. De victu attenuante. c. 1; p433 13–16
    PubMedGoogle Scholar
  • 76 Galen. De venae sect. adv. Erasistrateos Romae degentes, c. 8; vol. 11; p. 239
    PubMedGoogle Scholar
  • 77 New King James Bible, Mark 9:14–29. Carmel, NY: Guideposts; 1982
    Google Scholar
  • 78 Guelpa G, Marie A. La lutte contre l'epilepsie par la desintoxication et par la reeducation alimentaire. Rev Ther Med-Chirurg 1911; 78: 8-13
    PubMedGoogle Scholar
  • 79 Wheless JW. History and origin of the ketogenic diet. In: Stafstrom CE, Rho JM, eds. Epilepsy and the Ketogenic Diet. Totowa, NJ: Humana Press; 2004
    CrossrefGoogle Scholar
  • 80 Geyelin HR. Fasting as method for treating epilepsy. Med Rec 1921; 99: 1037-1039
    Google Scholar
  • 81 Woodyatt RT. Objects and method of diet adjustment in diabetics. Arch Intern Med 1921; 28: 125-141
    CrossrefPubMedGoogle Scholar
  • 82 Lennox WG, Cobb S. Studies in epilepsy. VIII: the clinical effect of fasting. Arch Neurol Psychiatry 1928; 20: 771-779
    Google Scholar
  • 83 Wilder RM. The effect of ketonemia on the course of epilepsy. Mayo Clin Bull 1921; 2: 307-309
    PubMedGoogle Scholar
  • 84 Peterman MG. The ketogenic diet in epilepsy. JAMA 1925; 84: 1979-1982
    CrossrefPubMedGoogle Scholar
  • 85 Barborka CJ. Epilepsy in adults: results of treatment by ketogenic diet in one hundred cases. Arch Neurol Psychiatry 1930; 23: 904-914
    CrossrefPubMedGoogle Scholar
  • 86 Huttenlocher PR, Wilbourn AJ, Signore JM. Medium-chain triglycerides as a therapy for intractable childhood epilepsy. Neurology 1971; 21 (11) 1097-1103
    CrossrefPubMedGoogle Scholar
  • 87 Kinsman SL, Vining EP, Quaskey SA, Mellits D, Freeman JM. Efficacy of the ketogenic diet for intractable seizure disorders: review of 58 cases. Epilepsia 1992; 33 (6) 1132-1136
    CrossrefPubMedGoogle Scholar
  • 88 Dateline NBC Medical Secrets. Ketogenic diet. October 26, 1994. Available at https://www.youtube.com/watch?v=q7d5gQrpdfo
    PubMedGoogle Scholar
  • 89 Zupec-Kania BA, Spellman E. An overview of the ketogenic diet for pediatric epilepsy. Nutr Clin Pract 2008; 23 (6) 589-596
    CrossrefPubMedGoogle Scholar
  • 90 El-Rashidy OF, Nassar MF, Abdel-Hamid IA , et al. Modified Atkins diet vs classic ketogenic formula in intractable epilepsy. Acta Neurol Scand 2013; 128 (6) 402-408
    CrossrefPubMedGoogle Scholar
  • 91 Lanska DJ. J.L. Corning and vagal nerve stimulation for seizures in the 1880s. Neurology 2002; 58 (Suppl. 03) 452-459
    CrossrefPubMedGoogle Scholar
  • 92 Zanchetti A, Wang SC, Moruzzi G. The effect of vagal afferent stimulation on the EEG pattern of the cat. Electroencephalogr Clin Neurophysiol 1952; 4 (3) 357-361
    CrossrefPubMedGoogle Scholar
  • 93 Chase MH, Nakamura Y, Clemente CD, Sterman MB. Afferent vagal stimulation: neurographic correlates of induced EEG synchronization and desynchronization. Brain Res 1967; 5 (2) 236-249
    CrossrefPubMedGoogle Scholar
  • 94 Chase MH, Nakamura Y. Cortical and subcortical EEG patterns of response to afferent abdominal vagal stimulation: neurographic correlates. Physiol Behav 1968; 3: 605-610
    CrossrefPubMedGoogle Scholar
  • 95 Zabara J. Peripheral control of hypersynchronous discharge in epilepsy. Electroencephal 1958; 61 (3) S162 DOI: 10.1016/0013-4694(85)90626-1.
    PubMedGoogle Scholar
  • 96 Woodbury DM, Woodbury JW. Effects of vagal stimulation on experimentally induced seizures in rats. Epilepsia 1990; 31 (Suppl. 02) S7-S19
    PubMedGoogle Scholar
  • 97 Terry R, Tarver WB, Zabara J. An implantable neurocybernetic prosthesis system. Epilepsia 1990; 31 (Suppl. 02) S33-S37
    CrossrefPubMedGoogle Scholar
  • 98 Penry JK, Dean JC. Prevention of intractable partial seizures by intermittent vagal stimulation in humans: preliminary results. Epilepsia 1990; 31 (Suppl. 02) S40-S43
    CrossrefPubMedGoogle Scholar
  • 99 Uthman BM, Wilder BJ, Hammond EJ, Reid SA. Efficacy and safety of vagus nerve stimulation in patients with complex partial seizures. Epilepsia 1990; 31 (Suppl. 02) S44-S50
    CrossrefPubMedGoogle Scholar
  • 100 Cyberonics Issue Overview. http://www.cyberonics.com/sites/default/files/Issue-Overview-FINAL-2013.pdf . Accessed May 15, 2015
    PubMed
  • 101 Murphy JV ; The Pediatric VNS Study Group. Left vagal nerve stimulation in children with medically refractory epilepsy. J Pediatr 1999; 134 (5) 563-566
    CrossrefPubMedGoogle Scholar
  • 102 Kabir SM, Rajaraman C, Rittey C, Zaki HS, Kemeny AA, McMullan J. Vagus nerve stimulation in children with intractable epilepsy: indications, complications and outcome. Childs Nerv Syst 2009; 25 (9) 1097-1100
    CrossrefPubMedGoogle Scholar
  • 103 Arhan E, Serdaroglu A, Kurt G , et al. The efficacy of vagal nerve stimulation in children with pharmacoresistant epilepsy: practical experience at a Turkish tertiary referral center. Eur J Paediatr Neurol 2010; 14 (4) 334-339
    CrossrefPubMedGoogle Scholar
  • 104 Elliott RE, Rodgers SD, Bassani L , et al. Vagus nerve stimulation for children with treatment-resistant epilepsy: a consecutive series of 141 cases. J Neurosurg Pediatr 2011; 7 (5) 491-500
    CrossrefPubMedGoogle Scholar
  • 105 Thompson EM, Wozniak SE, Roberts CM, Kao A, Anderson VC, Selden NR. Vagus nerve stimulation for partial and generalized epilepsy from infancy to adolescence. J Neurosurg Pediatr 2012; 10 (3) 200-205
    CrossrefPubMedGoogle Scholar
  • 106 Terra VC, Furlanetti LL, Nunes AA , et al. Vagus nerve stimulation in pediatric patients: is it really worthwhile?. Epilepsy Behav 2014; 31: 329-333
    CrossrefPubMedGoogle Scholar
  • 107 Morris III GL, Gloss D, Buchhalter J, Mack KJ, Nickels K, Harden C. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013; 81 (16) 1453-1459
    CrossrefPubMedGoogle Scholar